Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS.
Feldman ER. et al, (2025), Genet Epidemiol, 49
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse.
Van Der Maas NG. et al, (2025), Blood Adv
Clonal tracing with somatic epimutations reveals dynamics of blood ageing.
Scherer M. et al, (2025), Nature
Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.
Jakobsen NA. et al, (2025), STAR Protoc, 6
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1
Agarwal P. et al, (2025), Nature
Genome-wide association study of somatic GATA1s mutations in newborns with Down Syndrome.
Li Y. et al, (2025), Blood Adv
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation
Hosseini A. et al, (2025), Nature
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
Daver NG. et al, (2025), Blood Journal
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner JF. et al, (2025), Blood
Genome-wide association studies of Down syndrome associated congenital heart defects
Feldman ER. et al, (2024)
Risk Stratification in Older Intensively Treated Patients With AML.
Versluis J. et al, (2024), J Clin Oncol
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Aksöz M. et al, (2024), Sci Immunol, 9
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.
Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506